All Articles

The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce their partnership with Tigerlily Foundation (Tigerlily) on Tigerlily’s #InclusionPledge. The #InclusionPledge is an unprecedented global, multistakeholder initiative focused on diversity, inclusion, and elimination of disparities for Black women living with breast cancer.

In the fall of 2013, Loriana Hernandez-Aldama was working as a high-profile health reporter and TV news anchor. She was fit, healthy, and busy with her career and 2-year-old son when acute bone pain woke her up in the middle of the night.

Every day in the United States, thousands of people are diagnosed with cancer, but very few are offered the opportunity to participate in a clinical trial, and only a small fraction of those come from underrepresented populations, according to Carmen E. Guerra, MD, MSCE, FACP, associate director of Diversity and Outreach at Abramson Cancer Center in Philadelphia.

To assist in the practice of holistic care, AONN+ has established the Integrative Health Committee to help identify the modalities that fit seamlessly into the oncology care landscape.

Navigators at the Miami Cancer Institute (MCI) have built a successful navigation program database to track patient care delivery and report metrics, according to Morgan Nestingen, MSN, APRN, AGCNS-BC, NEA-BC, OCN, ONN-CG, director of Nursing, Patient Intake and Navigation Services at MCI.

A recently published case study found sotorasib efficacious and safe as first-line therapy for non–small cell lung cancer harboring the KRAS G12C mutation.

A Canadian study found that next-generation sequencing identified more mutations, had a faster turnaround time, and was more cost-effective than single-gene testing when used in patients with non–small cell lung cancer.

A recent review of liquid biopsy studies found it useful in detecting circulating tumor DNA in patients with early and select advanced non–small cell lung cancer.

A recent review discussed multiple ongoing studies evaluating KRAS G12C inhibitors for the treatment of non–small cell lung cancer harboring the KRAS G12C mutation.

Bispecific antibodies are unique antibody constructs that simultaneously bind 2 antigens, typically targeting an antigen on myeloma cells and a molecule on an immune cell. By using the patient’s immune system to destroy the malignant plasma cells, bispecific antibodies offer a promising treatment to overcome immunosuppression for patients with relapsing/refractory MM (RRMM).⁴